Future Market Insights has projected a robust growth trajectory for the Global Post-Traumatic Stress Disorder (PTSD) treatment Industry during the forecast period from 2023 to 2033. With a noteworthy Compound Annual Growth Rate (CAGR) of 5%, the market is poised to achieve a remarkable valuation of US$ 27.37 billion by the year 2033.
The surge in market value is underlined by the escalating prevalence of PTSD on a global scale. According to the National Center for PTSD, an estimated 7-8% of the US population is anticipated to experience PTSD at some point in their lives. Notably, higher rates are observed among military veterans and individuals who have undergone traumatic events such as sexual assault.
The impact of the COVID-19 pandemic is also acknowledged as a significant catalyst for PTSD. Healthcare workers, frontline responders, and those directly affected by the virus are particularly at an increased risk, contributing to the overall rise in PTSD cases.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16801
There is also a growing focus on the use of digital therapeutics and other non-pharmacological interventions for the treatment of PTSD. One example is the use of virtual reality exposure therapy (VRET), which has shown promising results in reducing PTSD symptoms by allowing individuals to confront their trauma in a safe and controlled environment. Several companies, including Limbix and Psious, are developing VRET platforms for the treatment of PTSD and other mental health conditions.
Key Takeaways from the Global Post-Traumatic Stress Disorder (PTSD) Treatment Industry Study
- The post-traumatic stress disorder (PTSD) treatment market is expected to grow at a value of 5% CAGR in the forecast period 2023 to 2033.
- By drug class, antidepressants are expected to hold 41% of the market share in 2023 for post-traumatic stress disorder (PTSD) treatment market.
- North America is expected to possess 43% market share for post-traumatic stress disorder (PTSD) treatment market in 2023.
- Europe post-traumatic stress disorder (PTSD) treatment market size is expected to possess 42% market share in 2023.
“As the prevalence of PTSD continues to rise, the need for effective and accessible treatments will only become more pressing. While there is still much work to be done, the growing focus on PTSD treatment is a positive step forward in improving the lives of individuals affected by this debilitating condition,”states an FMI analyst.
Reach Out to Our Analyst For Your Queries
https://www.futuremarketinsights.com/ask-question/rep-gb-16801
Global Post-Traumatic Stress Disorder (PTSD) Treatment Industry Competitive Landscape
Key players in the post-traumatic stress disorder (PTSD) treatment market are Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceutical Development & Commercialization, Inc., Bionomics Limited, Merck KGaA, Pfizer Inc., Aurobindo Pharma Limited, GlaxoSmithKline plc, Viatris Inc., Jubilant Pharma
- Otsuka has also partnered with the U.S. Department of Veterans Affairs (VA) to conduct a clinical trial of a medication called samidorphan (ALKS 5461) for the treatment of PTSD. Samidorphan is an opioid system modulator being investigated for its ability to reduce symptoms of PTSD, including anxiety, depression, and hyperarousal.
- Bionomics Limited is a biopharmaceutical company that has developed a medication called BNC210, which is being investigated as a potential treatment for PTSD (Post-Traumatic Stress Disorder). BNC210 is a small molecule drug that acts as a negative allosteric modulator of the α7 nicotinic acetylcholine receptor (α7 nAChR), which is thought to play a role in the development and maintenance of PTSD symptoms.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Post-traumatic stress disorder (PTSD) treatment market, presenting a historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights based on Drug Class (Antidepressants, Anti-anxiety Drugs, Antipsychotics, Other Drug Classes) Distribution Channel (Retail Pharmacies and Online Pharmacies) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa)
Grab Your Report on Discount Before It’s Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-16801
Key Segments Profiled in the Global Post-Traumatic Stress Disorder (PTSD) Treatment Industry Survey
By Drug Class:
- Antidepressants
- Anti-anxiety Drugs
- Antipsychotics
- Other Drug Classes
By Distribution Channel:
- Retail Pharmacies
- Online Pharmacies
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
